The United States faces a silent crisis: strokes cost the economy over , with cryptogenic strokes—those without an identifiable cause—accounting for nearly 30% of cases. Yet, a critical tool to address this burden, , remains vastly underpenetrated in the U.S. compared to Europe. For investors, this disparity presents a rare opportunity to capitalize on in a medtech sector primed for explosive demand.

While Europe’s adoption of pfo closure devices for cryptogenic stroke prevention has surged——the U.S. lags far behind, with only . This discrepancy stems from a combination of , reimbursement hurdles, and clinical inertia. However, three critical shifts are now reversing this trend:

The U.S. spends over on cryptogenic stroke care, with costs rising as the population ages. PFO closure devices offer a : preventing recurrent strokes reduces hospitalizations and long-term disability costs. For medtech firms, this translates into , growing at a .

Yet, current valuations for leading players like and (part of the European market) reflect little of this upside. Why?

While Abbott dominates with its , smaller peers are innovating aggressively:
- : Its Cardioshield device targets , a segment underserved by Abbott’s offerings. Though private, its market share (est. ) signals undervalued public peers.
- : Leverages , reducing procedural risks and accelerating adoption.
- : Its holds and is gaining traction in the U.S. through partnerships.

The PFO closure market is at an , yet stocks like Abbott trade at —a discount to medtech peers. This undervaluation ignores:
- (vs. $20 million today).
- , creating a of insurer support and patient demand.

The PFO closure market is a in a crowded medtech landscape. With Europe’s success as a template, U.S. adoption is primed to explode. For investors, now is the time to position in or undervalued giants like Abbott, before Wall Street catches on. The $1.3B stroke burden isn’t just a problem—it’s a goldmine waiting to be unlocked.

Act now: PFO closure stocks are cheap. They won’t stay that way for long.